Keywords
MedicineProteinuriaInternal medicineBlood pressurePost-hoc analysisClinical endpointRenal functionDiseaseKidney diseaseEnd stage renal diseaseClinical trialUrologyCardiologyKidney
Affiliated Institutions
Related Publications
The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has enr...
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
Racial and ethnic minority populations are growing segments of our society. The prevalence of hypertension in these populations differs across groups, and control rates are not ...
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Chronic treatment of saline-drinking stroke-prone spontaneously hypertensive rats (SHRSP) with agents that interfere with the formation or actions of angiotensin II (Ang II) pre...
Blood Pressure and End-Stage Renal Disease in Men
Elevations of blood pressure are a strong independent risk factor for end-stage renal disease; interventions to prevent the disease need to emphasize the prevention and control ...
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes. This protection is independent of the re...
Publication Info
- Year
- 2006
- Type
- letter
- Volume
- 367
- Issue
- 9514
- Pages
- 900-900
- Citations
- 15
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
15
OpenAlex
Cite This
Johannes F.E. Mann,
Eberhard Ritz,
Regina Kunz
(2006).
Renoprotective effects of renin-angiotensin-system inhibitors.
The Lancet
, 367
(9514)
, 900-900.
https://doi.org/10.1016/s0140-6736(06)68375-x
Identifiers
- DOI
- 10.1016/s0140-6736(06)68375-x